{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:22:09Z","timestamp":1783110129480,"version":"3.54.6"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00406-019-01058-1","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T08:02:45Z","timestamp":1566460965000},"page":"107-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacotherapy of psychiatric inpatients with adjustment disorder: current status and changes between 2000 and 2016"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0909-570X","authenticated-orcid":false,"given":"Timo","family":"Greiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Haack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermin","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Grohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Faltraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Heinze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,22]]},"reference":[{"key":"1058_CR1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2147\/NDT.S92637","volume":"12","author":"A Anastasia","year":"2016","unstructured":"Anastasia A, Colletti C, Cuoco V, Quartini A, Urso S, Rinaldi R et al (2016) Demographic variables, clinical aspects, and medicolegal implications in a population of patients with adjustment disorder. Neuropsychiatr Dis Treat 12:737\u2013743. \nhttps:\/\/doi.org\/10.2147\/NDT.S92637","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"1058_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/(SICI)1099-1077(199607)11:4<293::AID-HUP771>3.0.CO;2-Z","volume":"11","author":"M Annseau","year":"1996","unstructured":"Annseau M, Bataille M, Briole G, De Nayer A, Fauch\u00e8re PA, Ferrero F et al (1996) Controlled comparison of tianeptine, alprazolam and mianserin in the treatment of adjustment disorder with anxiety and depression. Hum Psychopharmacol Clin Exp 11(4):293\u2013298","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"13","key":"1058_CR3","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.1979.03300130045021","volume":"242","author":"FJ Ayd","year":"1979","unstructured":"Ayd FJ (1979) Benzodiazepines: dependence and Withdrawal. JAMA 242(13):1401\u20131402","journal-title":"JAMA"},{"key":"1058_CR4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1192\/bjp.179.4.308","volume":"179","author":"JL Ayuso-Mateos","year":"2001","unstructured":"Ayuso-Mateos JL, V\u00e1zquez-Barquero JL, Dowrick C, Lehtinen V, Dalgard OS, Casey P et al (2001) Depressive disorders in Europe: prevalence figures from the ODIN study. Br J Psychiatry 179:308\u2013316","journal-title":"Br J Psychiatry"},{"key":"1058_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jad.2017.10.034","volume":"227","author":"R Bachem","year":"2017","unstructured":"Bachem R, Casey P (2017) Adjustment disorder: a diagnosis whose time has come. J Affect Disord 227:243\u2013253","journal-title":"J Affect Disord"},{"key":"1058_CR6","volume-title":"Anpassungsst\u00f6rung und Akute Belastungsreaktion","author":"J Bengel","year":"2010","unstructured":"Bengel J, Hubert S (2010) Anpassungsst\u00f6rung und Akute Belastungsreaktion. Hogrefe, G\u00f6ttingen"},{"issue":"2","key":"1058_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1472-8206.1997.tb00179.x","volume":"11","author":"M Bourin","year":"1997","unstructured":"Bourin M, Bougerol T, Guitton B, Broutin E (1997) A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo. Fundam Clin Pharmacol 11(2):127\u2013132","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"1058_CR8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.euroneuro.2015.03.017","volume":"25","author":"R Bridler","year":"2015","unstructured":"Bridler R, H\u00e4berle A, M\u00fcller ST, Cattapan K, Grohmann R, Toto S et al (2015) Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol 25(6):763\u2013772. \nhttps:\/\/doi.org\/10.1016\/j.euroneuro.2015.03.017","journal-title":"Eur Neuropsychopharmacol"},{"key":"1058_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1192\/bjp.179.6.479","volume":"179","author":"P Casey","year":"2001","unstructured":"Casey P, Dowrick C, Wilkinson G (2001) Adjustment disorder\u2014fault line in the psychiatric glossary. Br J Psychiatry 179:479\u2013481","journal-title":"Br J Psychiatry"},{"issue":"11","key":"1058_CR10","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2165\/11311000-000000000-00000","volume":"23","author":"P Casey","year":"2009","unstructured":"Casey P (2009) Adjustment disorder: epidemiology. Diagnosis and Treatment CNS Drugs 23(11):927\u2013938. \nhttps:\/\/doi.org\/10.2165\/11311000-000000000-00000","journal-title":"Diagnosis and Treatment CNS Drugs"},{"key":"1058_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2466\/2Fpr0.1989.64.1.51","volume":"64","author":"D De Leo","year":"1989","unstructured":"De Leo D (1989) Treatment of adjustment disorders: a comparative evaluation. Psychol Rep 64:51\u201354. \nhttps:\/\/doi.org\/10.2466\/2Fpr0.1989.64.1.51","journal-title":"Psychol Rep"},{"issue":"5","key":"1058_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/2F030006059902700502","volume":"27","author":"S De Wit","year":"1999","unstructured":"De Wit S, Cremers L, Hirsch D, Zulian C, Clumeck N, Kormoss N (1999) Efficacy and safety of trazodone versus clorazepate in the treatment of HIV-positive subjects with adjustment disorders: a pilot study. J Int Med Res 27(5):223\u2013232. \nhttps:\/\/doi.org\/10.1177\/2F030006059902700502","journal-title":"J Int Med Res"},{"key":"1058_CR13","volume-title":"Internationale Klassifikation psychischer St\u00f6rungen ICD-10 Kapitel V (F)","author":"H Dilling","year":"2010","unstructured":"Dilling H, Mombour W, Schmidt MH (2010) Internationale Klassifikation psychischer St\u00f6rungen ICD-10 Kapitel V (F). Hans Huber, Bern"},{"issue":"Sup1","key":"1058_CR14","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1080\/15622975.2018.1467041","volume":"19","author":"M Domhard","year":"2018","unstructured":"Domhard M, Baumeister H (2018) Psychotherapy of adjustment disorders: current state and future directions. World J Biol Psychiatry 19(Sup1):S21\u2013S35. \nhttps:\/\/doi.org\/10.1080\/15622975.2018.1467041","journal-title":"World J Biol Psychiatry"},{"issue":"Suppl 1","key":"1058_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1055\/s-2004-815506","volume":"37","author":"RR Engel","year":"2004","unstructured":"Engel RR, Grohmann R, R\u00fcther E, Hippius H (2004) Research methods in drug surveillance. Pharmacopsychiatry 37(Suppl 1):12\u201315. \nhttps:\/\/doi.org\/10.1055\/s-2004-815506","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"1058_CR16","first-page":"202","volume":"5","author":"G Flatten","year":"2011","unstructured":"Flatten G, Gast U, Hofmann A, Knaevelsrud C, Lampe A, Liebermann P et al (2011) S3\u2013LEITLINIE: Posttraumatische Belastungsst\u00f6rung ICD-10: F43.1. Trauma Gewalt 5(3):202\u2013210","journal-title":"Trauma Gewalt"},{"key":"1058_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1176\/ajp.152.3.459","volume":"152","author":"WM Greenberg","year":"1995","unstructured":"Greenberg WM, Rosenfeld DN, Ortega EA (1995) Adjustment disorder as an admission diagnosis. Am J Psychiatry 152:459\u2013461. \nhttps:\/\/doi.org\/10.1176\/ajp.152.3.459","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1058_CR18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jad.2011.10.033","volume":"136","author":"W Greil","year":"2012","unstructured":"Greil W, H\u00e4berle A, Haueis P, Grohmann R, Russmann S (2012) Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord 136(3):534\u2013542. \nhttps:\/\/doi.org\/10.1016\/j.jad.2011.10.033","journal-title":"J Affect Disord"},{"issue":"Suppl 1","key":"1058_CR19","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1055\/s-2004-815505","volume":"37","author":"R Grohmann","year":"2004","unstructured":"Grohmann R, Engel RR, R\u00fcther E, Hippius H (2004) The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37(Suppl 1):S4\u2013S11. \nhttps:\/\/doi.org\/10.1055\/s-2004-815505","journal-title":"Pharmacopsychiatry"},{"key":"1058_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00406-014-0523-7","volume":"265","author":"AK Holl","year":"2015","unstructured":"Holl AK, Grohmann R, Letmaier M, Painold A, M\u00f6rkl S, Toto S et al (2015) Pharmacotherapy of anxiety disorders in German-speaking countries: current status and changes between 1994 and 2011. Eur Arch Psychiatry Clin Neurosci 265:199\u2013208. \nhttps:\/\/doi.org\/10.1007\/s00406-014-0523-7","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1058_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0165-0327(01)00390-1","volume":"71","author":"R Jones","year":"2002","unstructured":"Jones R, Yates WR, Zhou MH (2002) Readmission rates for adjustment disorders: comparison with other mood disorders. J Affect Disord 71:199\u2013203","journal-title":"J Affect Disord"},{"issue":"12","key":"1058_CR22","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1176\/appi.ps.53.12.1623","volume":"53","author":"LM Koran","year":"2003","unstructured":"Koran LM, Sheline Y, Imai K, Kelsey TG, Freedland KE, Mathews J et al (2003) Medical disorders among patients admitted to a public sector psychiatric inpatient unit. Psychiatr Serv 53(12):1623\u20131625. \nhttps:\/\/doi.org\/10.1176\/appi.ps.53.12.1623","journal-title":"Psychiatr Serv"},{"issue":"7","key":"1058_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jpsychires.2006.03.006","volume":"41","author":"H Kumano","year":"2007","unstructured":"Kumano H, Ida I, Oshima A, Takahashi K, Yuuki N, Amanuma M et al (2007) Brain metabolic changes associated with predispotion to onset of major depressive disorder and adjustment disorder in cancer patients\u2013a preliminary PET study. J Psychiatr Res 41(7):591\u2013599. \nhttps:\/\/doi.org\/10.1016\/j.jpsychires.2006.03.006","journal-title":"J Psychiatr Res"},{"issue":"S1","key":"1058_CR24","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1080\/15622975.2018.1449967","volume":"19","author":"A Maercker","year":"2018","unstructured":"Maercker A, Lorenz L (2018) Adjustment disorder diagnosis: improving clinical utility. World J Biol Psychiatry 19(S1):S3\u2013S13. \nhttps:\/\/doi.org\/10.1080\/15622975.2018.1449967","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"1058_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00004850-200505000-00002","volume":"20","author":"N Moore","year":"2005","unstructured":"Moore N, Verdoux H, Bruno F (2005) Prospective, multicentre, randomised, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 20(3):131\u2013137","journal-title":"Int Clin Psychopharmacol"},{"key":"1058_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s00787-005-0457-8","volume":"14","author":"M Pelkonen","year":"2005","unstructured":"Pelkonen M, Marttunen M, Henriksson M, L\u00f6nnqvist J (2005) Suicidality in adjustment disorder, clinical characteristics of adolescent outpatients. Eur Child Adolesc Psychiatry 14:174\u2013180. \nhttps:\/\/doi.org\/10.1007\/s00787-005-0457-8","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"1058_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jad.2016.04.035","volume":"200","author":"C Poppe","year":"2016","unstructured":"Poppe C, M\u00fcller ST, Greil W, Walder A, Grohmann R, St\u00fcbner S (2016) Pharmacotherapy for obsessive compulsive disorder in clinical practice\u2014data of 842 inpatients from the International AMSP Project between 1994 and 2012. J Affect Disord 200:89\u201396. \nhttps:\/\/doi.org\/10.1016\/j.jad.2016.04.035","journal-title":"J Affect Disord"},{"issue":"3","key":"1058_CR28","first-page":"238","volume":"27","author":"W Semaan","year":"2001","unstructured":"Semaan W, Hergueta T, Bloch J, Charpak Y, Duburcq A, Le Guern ME et al (2001) Cross-sectional study of the prevalence of adjustment disorder with anxiety in general practice. Encephale 27(3):238\u2013244","journal-title":"Encephale"},{"key":"1058_CR29","first-page":"569","volume":"24","author":"D Servant","year":"1998","unstructured":"Servant D, Graziani PL, Moyse D, Parquet PJ (1998) Treatment of adjustment disorder with anxiety: efficacy and tolerance of etifoxine in a double-blind controlled study. Encephale 24:569\u2013574","journal-title":"Encephale"},{"key":"1058_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1176\/appi.ajp.157.4.581","volume":"157","author":"MK Shear","year":"2000","unstructured":"Shear MK, Greeno C, Kang J, Ludewig D, Frank E, Swartz HA et al (2000) Diagnosis of nonpsychotic patients in community clinics. Am J Psychiatry 157:581\u2013587. \nhttps:\/\/doi.org\/10.1176\/appi.ajp.157.4.581","journal-title":"Am J Psychiatry"},{"key":"1058_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0165-0327(96)00025-0","volume":"39","author":"G Spalletta","year":"1996","unstructured":"Spalletta G, Troisi A, Saracco M, Ciani N, Pasini A (1996) Symptomprofile, axis II comorbidity and suicidal behavior in young males with DSM-III-R depressive illness. J Affect Disord 39:141\u2013148","journal-title":"J Affect Disord"},{"issue":"7","key":"1058_CR32","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","volume":"30","author":"E Spina","year":"2008","unstructured":"Spina E, Santoro V, D\u2019Arrigo C (2008) Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30(7):1206\u20131227","journal-title":"Clin Ther"},{"key":"1058_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12325-015-0176-6","volume":"32","author":"DJ Stein","year":"2015","unstructured":"Stein DJ (2015) Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial. Adv Ther 32:57\u201368. \nhttps:\/\/doi.org\/10.1007\/s12325-015-0176-6","journal-title":"Adv Ther"},{"issue":"S1","key":"1058_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/15622975.2018.1492736","volume":"19","author":"DJ Stein","year":"2018","unstructured":"Stein DJ (2018) Pharmacotherapy of adjustment disorder: a review. World J Biol Psychiatry 19(S1):46\u201352. \nhttps:\/\/doi.org\/10.1080\/15622975.2018.1492736","journal-title":"World J Biol Psychiatry"},{"issue":"1","key":"1058_CR35","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1080\/15622975.2018.1459049","volume":"19","author":"JJ Strain","year":"2018","unstructured":"Strain JJ (2018) The psychobiology of stress, depression, adjustment disorders and resilience. World J Biol Psychiatry 19(1):S214\u2013S220. \nhttps:\/\/doi.org\/10.1080\/15622975.2018.1459049","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"1058_CR36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S0924-9338(00)00226-1","volume":"15","author":"J Tripodianakis","year":"2000","unstructured":"Tripodianakis J, Markianos M, Sarantidis D, Leotsakou C (2000) Neurochemical variables in subjects with adjustment disorder after suicide attempts. Eur Psychiatry 15(3):190\u2013195","journal-title":"Eur Psychiatry"},{"issue":"4","key":"1058_CR37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/2F0269881114562090","volume":"29","author":"SL Young","year":"2014","unstructured":"Young SL, Taylor M, Lawrie SM (2014) \u201cFirst do no harm.\u201d A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol 29(4):353\u2013362. \nhttps:\/\/doi.org\/10.1177\/2F0269881114562090","journal-title":"J Psychopharmacol"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-019-01058-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-019-01058-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-019-01058-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T23:13:54Z","timestamp":1597965234000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-019-01058-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,22]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1058"],"URL":"https:\/\/doi.org\/10.1007\/s00406-019-01058-1","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,22]]},"assertion":[{"value":"1 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"T Greiner, B. Haack, F. Faltraco, M. Schneider and M. Heinze declare no conflict of interests. The AMSP Drug Safety Programme is based on non-profit associations in the German-speaking countries Germany, Austria and Switzerland. In recent years, financial support has been contributed by almost all the pharmaceutical companies involved in CNS research. Since 1993 educational and research grants have been awarded by the following pharmaceutical companies to the three national non-profit associations of the AMSP: <i>Austrian companies:<\/i> AstraZeneca \u00d6sterreich GmbH, Boehringer Ingelheim Austria, Bristol\u2013Myers Squibb GmbH, CSC Pharmaceuticals GmbH, Eli Lilly GmbH, Germania Pharma GmbH, GlaxoSmithKline Pharma GmbH, Janssen-Cilag Pharma GmbH, Lundbeck GmbH, Novartis Pharma GmbH, Pfizer Med Inform, Servier Pharma Austria, Wyeth Lederle Pharma GmbH. <i>German companies:<\/i> Abbott GmbH & Co. KG, AstraZeneca GmbH, Aventis Pharma Deutschland GmbH GE\u2013O\/R\/N, Bayer Vital GmbH & Co. KG, Boehringer Mannheim GmbH, Bristol-Myers-Squibb, Ciba Geigy GmbH, Desitin Arzneimittel GmbH, Duphar Pharma GmbH & Co. KG, Eisai GmbH, esparma GmbH Arzneimittel, GlaxoSmithKline Pharma GmbH & Co. KG, Hoffmann-La Roche AG Medical Affairs, Janssen-Cilag GmbH, Janssen Research Foundation, Knoll Deutschland GmbH, Lilly Deutschland GmbH Niederlassung Bad Homburg, Lundbeck GmbH & Co. KG, Nordmark Arzneimittel GmbH, Novartis Pharma GmbH, Organon GmbH, Otsuka-Pharma Frankfurt, Pfizer GmbH, Pharmacia & Upjohn GmbH, Promonta Lundbeck Arzneimittel, Rhone-Poulenc Rohrer, Sanofi-Synthelabo GmbH, Sanofi-Aventis Deutschland, Schering AG, Servier Pharma, SmithKlineBeecham Pharma GmbH, Solvay Arzneimittel GmbH, Synthelabo Arzneimittel GmbH, Dr Wilmar Schwabe GmbH & Co., Thiemann Arzneimittel GmbH, Trommsdorff GmbH & Co. KG Arzneimittel, Troponwerke GmbH & Co. KG, Upjohn GmbH, Wander Pharma GmbH, Wyeth-Pharma GmbH. <i>Swiss companies:<\/i> AHP (Schweiz) AG, AstraZeneca AG, Bristol\u2013Myers Squibb AG, Desitin Pharma GmbH, Eli Lilly (Suisse) S.A., Essex Chemie AG, GlaxoSmithKline AG, Janssen-Cilag AG, Lundbeck (Suisse) AG, Mepha Schweiz AG\/Teva, MSD Merck Sharp & Dohme AG, Organon AG, Pfizer AG, Pharmacia, Sandoz Pharmaceuticals AG, Sanofi-Aventis (Suisse) S.A., Sanofi-Synthe\u00b4labo SA, Servier SA, SmithKlineBeecham AG, Solvay Pharma AG, Vifor SA, Wyeth AHP (Suisse) AG, Wyeth Pharmaceuticals AG. S. Bleich, R. Grohmann and S. Toto are project managers of the AMSP programme. S. Toto has been a member of the advisory board for Otsouka and has received speaker\u2018s honoria from Janssen-Cilag, Lundbeck, Otsouka and Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}